Profile data is unavailable for this security.
About the company
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
- Revenue in USD (TTM)81.00k
- Net income in USD-46.45m
- Incorporated2013
- Employees49.00
- LocationActinium Pharmaceuticals Inc100 Park Ave., 23Rd FloorNEW YORK 10017United StatesUSA
- Phone+1 (646) 677-3870
- Fax+1 (845) 818-3588
- Websitehttps://www.actiniumpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Black Diamond Therapeutics Inc | 0.00 | -79.79m | 275.64m | 54.00 | -- | 2.47 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
TriSalus Life Sciences Inc | 21.98m | -68.07m | 275.67m | 112.00 | -- | -- | -- | 12.54 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
ESSA Pharma Inc | 0.00 | -27.73m | 276.05m | 50.00 | -- | 2.07 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
CorMedix Inc | 0.00 | -50.24m | 277.65m | 82.00 | -- | 4.78 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
Sanara Medtech Inc | 68.00m | -4.89m | 280.58m | 107.00 | -- | 6.48 | -- | 4.13 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
Adaptimmune Therapeutics PLC - ADR | 18.36m | -163.41m | 281.12m | 449.00 | -- | 11.53 | -- | 15.31 | -0.7285 | -0.7285 | 0.0834 | 0.0954 | 0.0672 | -- | 3.63 | 40,886.41 | -59.85 | -41.19 | -78.55 | -48.21 | -- | -- | -890.13 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
Nature's Sunshine Products Inc | 447.68m | 16.54m | 282.45m | 814.00 | 17.78 | 1.84 | 9.47 | 0.6309 | 0.8479 | 0.8479 | 22.96 | 8.20 | 1.86 | 1.91 | 44.39 | 549,974.20 | 7.33 | 6.57 | 10.66 | 9.41 | 72.19 | 72.69 | 3.94 | 3.74 | 1.42 | -- | 0.013 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
Caribou Biosciences Inc | 33.40m | -115.26m | 282.69m | 158.00 | -- | 0.8235 | -- | 8.46 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 287.87m | 122.00 | -- | 2.75 | -- | 401.45 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 288.60m | 49.00 | -- | 6.50 | -- | 3,562.98 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Aquestive Therapeutics Inc | 51.50m | -28.77m | 290.41m | 135.00 | -- | -- | -- | 5.64 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
XOMA Corp | 5.81m | -45.09m | 291.31m | 13.00 | -- | 3.54 | -- | 50.13 | -3.92 | -3.92 | 0.5053 | 7.08 | 0.0329 | -- | 1,291.33 | 447,000.00 | -22.44 | -4.55 | -24.19 | -4.94 | -- | -- | -681.69 | -31.87 | -- | -24.55 | 0.5944 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
Inozyme Pharma Inc | 0.00 | -77.11m | 292.58m | 59.00 | -- | 2.46 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
Verastem Inc | 0.00 | -105.52m | 294.03m | 73.00 | -- | 11.72 | -- | -- | -4.40 | -4.40 | 0.00 | 1.83 | 0.00 | -- | -- | 0.00 | -86.34 | -62.70 | -108.04 | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.4703 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 301.15m | 133.00 | -- | 1.63 | -- | 283.04 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.58m | 5.37% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.39m | 4.75% |
District 2 Capital LPas of 31 Dec 2023 | 826.43k | 2.81% |
Geode Capital Management LLCas of 31 Mar 2024 | 595.72k | 2.03% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 550.85k | 1.87% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 230.61k | 0.78% |
Verition Fund Management LLCas of 31 Mar 2024 | 196.44k | 0.67% |
Marshall Wace LLPas of 31 Mar 2024 | 152.47k | 0.52% |
Brandywine Global Investment Management LLCas of 31 Mar 2024 | 145.60k | 0.50% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 144.47k | 0.49% |